- Home
- SKIN vs TTRX Comparison
SKIN vs TTRX Comparison
Compare SKIN & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIN | TTRX |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.9M | 116.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKIN | TTRX |
|---|---|---|
| Price | $1.14 | $3.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 682.4K | 13.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $334,294,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $2.57 |
| 52 Week High | $2.69 | $5.98 |
Technical Indicators
Market Signals| Indicator | SKIN | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 43.86 |
| Support Level | $0.87 | $2.64 |
| Resistance Level | $1.69 | $4.01 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 75.65 | 33.33 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.